Stockscreener 앱 받기
46.55
0.67%
0.31
전일 마감가:
$46.24
열려 있는:
$46.8
하루 거래량:
3.63M
Relative Volume:
1.59
시가총액:
$8.70B
수익:
$29.52M
순이익/손실:
$-567.06M
주가수익비율:
-12.72
EPS:
-3.66
순현금흐름:
$-551.11M
1주 성능:
+14.94%
1개월 성능:
+32.02%
6개월 성능:
+18.75%
1년 성능:
+10.91%
1일 변동 폭
$45.18
$47.04
1주일 범위
$39.73
$47.04
52주 변동 폭
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
46.55 | 7.56B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines (NASDAQ:RVMD) Given New $66.00 Price Target at Needham & Company LLC - MarketBeat
Dynamic Technology Lab Private Ltd Invests $502,000 in Revolution Medicines, Inc. $RVMD - MarketBeat
Siren L.L.C. Sells 7,793 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution’s Daraxonrasib Data Bolster Phase III Case Amid RAS Cancer Push - insights.citeline.com
Goldman Sachs Raises Price Target for RVMD to $73.00, Maintains Buy Rating | RVMD Stock News - GuruFocus
Fred Alger Management LLC Has $4.15 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Stock Skyrockets: What’s Next? - timothysykes.com
Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results - simplywall.st
Adage Capital Partners GP L.L.C. Has $13.93 Million Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Benzinga
Revolution Medicines’ Surging Potential: What’s Happening? - StocksToTrade
Revolution Medicines: Shares Soar On Pancreatic Cancer Study WinI'm Sold (NASDAQ:RVMD) - Seeking Alpha
Stocks making the biggest moves midday: Delta Air Lines, Revolution Medicines, Centene and more - CNBC
Revolution Medicines announces results from daraxonrasib Phase 1 trials - TipRanks
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
Wedbush Raises Price Target on Revolution Medicines to $77 From $73, Keeps Outperform Rating - MarketScreener
Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines - TipRanks
Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick - Clinical Trials Arena
Promising Position of Revolution Medicines’ Zoldonrasib Justifies Buy Rating - TipRanks
Revolution Medicines price target raised to $70 from $67 at Wells Fargo - TipRanks
Cinctive Capital Management LP Sells 23,447 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Trexquant Investment LP Acquires New Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines - TipRanks
Granahan Investment Management LLC Acquires 7,322 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines reports promising pancreatic cancer drug results - Investing.com India
Revolution Medicines reports promising pancreatic cancer drug results By Investing.com - Investing.com South Africa
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - Seeking Alpha
Revolution Medicines Shares Under Pressure Despite Positive News - TipRanks
Revolution Medicines Reports Promising Phase 1 Study Results - TipRanks
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma - The Manila Times
Revolution Medicines Reports Promising Long-term Data for Daraxonrasib in Metastatic Pancreatic Cancer and Announces Phase 3 Trial Plans - Quiver Quantitative
Did Truist’s Coverage of RAS Pipeline Just Shift Revolution Medicines’ (RVMD) Investment Narrative? - simplywall.st
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at Truist Financial - MarketBeat
Revolution Medicines (RVMD): Assessing Valuation After Truist Highlights Potential of RAS-mutant Cancer Pipeline - Yahoo Finance
How does Revolution Medicines Inc. correlate with NasdaqJuly 2025 Macro Moves & Precise Swing Trade Alerts - Lancaster City Council
Revolution Medicines, Inc. $RVMD Holdings Lifted by Checkpoint Capital L.P. - MarketBeat
Published on: 2025-09-09 05:17:32 - 뉴스영
Support Zone Holds Steady for Revolution Medicines Inc. After Dip2025 Valuation Update & Smart Money Movement Tracker - beatles.ru
Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway? - Yahoo Finance
Revolution Medicines (RVMD): Exploring Valuation After Truist Coverage Highlights Pipeline Potential - simplywall.st
Revolution Medicines (NASDAQ:RVMD) Stock Price Up 5.2%Still a Buy? - MarketBeat
ADAR1 Capital Management LLC Acquires 7,136 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
BVF Inc. IL Boosts Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
What machine learning models say about Revolution Medicines Inc.July 2025 Catalysts & AI Forecast for Swing Trade Picks - Newser
What’s the recovery path for long term holders of Revolution Medicines Inc.July 2025 Breakouts & AI Optimized Trade Strategies - Newser
Will Revolution Medicines Inc. Equity Warrant stock go up soonMarket Movers & High Accuracy Buy Signal Tips - Newser
Institutional scanner results for Revolution Medicines Inc.Portfolio Gains Report & Daily Technical Forecast Reports - Newser
Strategies to average down on Revolution Medicines Inc. Equity Warrant - Newser
Short interest data insights for Revolution Medicines Inc. Equity WarrantMarket Growth Summary & Risk Managed Trade Strategies - Newser
Revolution Medicines stock initiated with Buy rating at Truist Securities By Investing.com - Investing.com Canada
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):